Trending

FDA, companies add 3 heartburn meds to recall amid cancer concerns

By Kelli Dugan, Cox Media Group National Content Desk
By Kelli Dugan, Cox Media Group National Content Desk

At least three antacids were added this week to a growing recall of the products due to potential cancer-causing contamination, multiple media outlets reported.

According to CNN, both Denton Pharma Inc. and Appco Pharma LLC recalled multiple batches of ranitidine tablets and ranitidine hydrochloride capsules due to the detection of a potentially carcinogenic impurity known as N-Nitrosodimethylamine, or NDMA.

The Denton recall affects unexpired lots of 150 mg and 300 mg ranitidine tablets, while the Appco action affects 150 mg and 300 mg batches of its ranitidine hydrochloride capsules, the network reported.

Meanwhile, Mylan Pharmaceuticals issued a voluntary recall of three lots of Nizatidine capsules, known more commonly as Axid, on the same contamination fears, KAIT reported.

According to the FDA, the Mylan products were distributed nationwide to wholesalers, mail order and retail pharmacies as well as a distributor between June 2017 and August 2018.

None of the companies involved in these most recent recalls have received any reports of adverse effects from the drugs, the FDA confirmed.



FDA, companies add 3 heartburn meds to recall amid cancer concerns A sample of NDMA, an impurity that has been linked to an increased risk for colorectal and uterine cancers, was found in samples of ranitidine, a drug used to treat and prevent heartburn by reducing stomach acid. It's sold under the brand name Zantac. Valisure, a small pharmacy that checks the composition of drugs, and is responsible for the world-wide recall of the heartburn drug Zantac. (Stan Godlewski /The Washington Post via Getty Images)


© 2020 Cox Media Group

Most Read